Y-mabs announces presentation of naxitamab data at asco

New york, may 26, 2023 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring interim clinical data on naxitamab, a recombinant, humanized anti-gd2 monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating factor (“gm-csf”) will be presented at the american society of clinical oncology (“asco”) annual meeting to be held june 2-6, 2023, in chicago, illinois.
YMAB Ratings Summary
YMAB Quant Ranking